Delaware
|
94-3023969
|
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
Incorporation)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Exhibit
No.
|
Description
|
|
10.1
|
Patent
License Agreement between the Company and MedImmune, Inc., dated July 17,
1997†
|
|
†
|
Certain
information in this exhibit has been omitted and previously filed
separately with the Securities and Exchange Commission pursuant to a
confidential treatment request under 17 C.F.R. Sections 200.80(b)(4)
and 24b-2.
|
PDL
BIOPHARMA, INC.
|
||
(Company)
|
||
By:
|
/s/ Christopher
Stone
|
|
Christopher
Stone
|
||
Vice
President, General Counsel and
Secretary
|
Exhibit
No.
|
Description
|
|
10.1
|
Patent
License Agreement between the Company and MedImmune, Inc., dated July 17,
1997†
|
|
†
|
Certain
information in this exhibit has been omitted and previously filed
separately with the Securities and Exchange Commission pursuant to a
confidential treatment request under 17 C.F.R. Sections 200.80(b)(4)
and 24b-2.
|